The US is currently well ahead of the rest of the world in the development and application of SB and its principles especially as they pertain to basic medical research and development. This lead is largely due to its earlier start in the academic arena. However, there is evidence of rapid development in both the UK/EU and Japan, and the gap is narrowing, particularly in the UK. From an industrial point of view, the Pharmaceutical Industry based in the US and UK can capitalize on these opportunities and gain the benefits of this techlogy. Many educational institutions (particularly their medical divisions) at present are heavily business-oriented, realize that in this particular industrial environment that every dollar counts.
Ales Prokop, Seth Michelson
Date of Publication
Medical Nursing & Ancillary Services
Springerbriefs in Pharmaceutical Science and Drug Development